Previous close | 16.35 |
Open | 16.34 |
Bid | 16.57 x N/A |
Ask | 16.60 x N/A |
Day's range | 16.20 - 16.73 |
52-week range | 16.17 - 30.25 |
Volume | |
Avg. volume | 5,186 |
Market cap | 14.322B |
Beta (5Y monthly) | 0.75 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.93 (5.72%) |
Ex-dividend date | 20 May 2024 |
1y target est | N/A |
In the most recent trading session, Walgreens Boots Alliance (WBA) closed at $17.53, indicating a +1.1% shift from the previous trading day.
Walgreens is ramping up its clinical trial offerings with Big Pharma players.
Walgreens Boots Alliance Inc. (NASDAQ:WBA) is facing tumultuous times as it grapples with a challenging turnaround, leading to a drastic decline in its stock value, marking its worst performance in over five years. The company’s shares plummeted by 18% in April, nearing a 26-year low, following a downward revision of its outlook. This revision was accompanied by concerns over decreased consumer spending and the revelation of a substantial unpaid tax liability amounting to $2.7 billion, adding to